Thalidomide in the treatment of leprosy

Microbes and Infection

Volumn 4, Issue 11, 2002, Pages 1193-1202

  Teo, Steve K ^a   Resztak, Ken E ^a   Scheffler, Michael A ^a   Kook, Karin A ^b   Zeldis, Jerry B ^a   Stirling, David I ^a   Thomas, Steve D ^a  

^a CELGENE CORPORATION   (United States)

^b Salamandra LLC   (United States)

Author keywords

Erythema nodosum leprosum; Leprosy; Thalidomide; Type 2 reaction

Indexed keywords

BCG VACCINE; CLOFAZIMINE; CORTICOSTEROID; CYTOKINE; PREDNISOLONE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; BACTERIAL TRANSMISSION; BCG VACCINATION; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CYTOKINE RELEASE; DISEASE CLASSIFICATION; DROWSINESS; DRUG ABSORPTION; DRUG EFFICACY; ERYTHEMA NODOSUM LEPROSUM; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOLOGY; INCIDENCE; INFECTION PREVENTION; LEPROMATOUS LEPROSY; LEPROSY; LONGITUDINAL STUDY; MICROBIOLOGY; MONOCYTE; MYCOBACTERIUM LEPRAE; NEUROLOGIC DISEASE; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; REVIEW; SEDATION; SIDE EFFECT; TERATOGENICITY; TUBERCULOID LEPROSY;

DRUG THERAPY, COMBINATION; ERYTHEMA NODOSUM; HUMANS; INCIDENCE; LEPROSTATIC AGENTS; LEPROSY; LEPROSY, LEPROMATOUS; MODELS, MOLECULAR; MYCOBACTERIUM LEPRAE; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

MYCOBACTERIUM; MYCOBACTERIUM LEPRAE;

EID: 0036753672     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(02)01645-3     Document Type: Review

References (38)

1. Sheskin J. Thalidomide in the treatment of lepra reaction. Clin. Pharmacol. Ther. 6:1965;303-306.
2. Franzblau S. Drug susceptibility testing of M. leprae in the BACTEC 460 system. Antimicrob. Agents Chemother. 33:1989;215-217.
3. Cole S., Eiglmeier K., Parkhill J. Massive gene decay in the leprosy bacillus. Nature. 409:2001;1007-1011.
4. Hunter S., Fujiwara T., Brennan P. Structure and antigenicity of the major specific glycolipid antigen of M. leprae. J. Biol. Chem. 257:1982;15072-15078.
5. Klebanoff S., Shepard C. Toxic effects of the peroxidase-hydrogen peroxide peroxide-halide antimicrobial system on M. leprae. Infect. Immun. 44:1984;534-536.
6. Cho S., Fujiwara T., Gelber R., Brennan P. Use of an artificial antigen containing the 3,6-di-O-methyl-beta-D-glycopyranosyl epitope for the serodiagnosis of leprosy. J. Infect. Dis. 150:1984;311-322.
7. Mehra V., Brennan P., Rada E., Convit J., Bloom R. Lymphocyte suppression in leprae induced by unique M. leprae glycolipid. Nature. 308:1984;194-196.
8. Weekly Epidemiol W.H.O. Record. 75:2000;225-232.
9. Style A. Early diagnosis and treatment of leprosy in the United States. Am. Family Phy. 52:1995;172-178.
10. Ridley D., Jopling W. A classification of leprosy for research purposes. Lepr. Rev. 33:1962;119-129.
11. Hastings R., Franzblau S. Chemotherapy of leprosy. Ann. Rev. Pharmacol. Toxicol. 28:1988;231-245.
12. Jolliffe D. Leprosy reactional states and their treatment. Brit. J. Derm. 97:1977;345-352.
13. Jacobson R., Trautman J. The diagnosis and treatment of leprosy. South. Med. J. 69:1976;979-985.
14. Convit J., Sampson C., Zuniga M., Smith P., Plata J., Silva J., Molina J., Pinardi M., Bloom B., Salgado A. Immunoprophylactic trial with combined Mycobacterium leprae/BCG vaccine against leprosy: preliminary results. Lancet. 339:1992;462-463.
15. Antia N. The significance of nerve involvement in leprosy. Plast. Reconstr. Surg. 54:1974;55-63.
16. Rose P., Waters M. Reversal reactions in leprosy and their management. Lepr. Rev. 62:1991;113-121.
17. Sampaio E., Sarno E., Galilly R., Cohn Z., Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. M. 173:1991;699-703.
18. WHO expert committee on leprosy . WHO technical report series #874. 7th report World Health Organization. 1998;Switzerland, Geneva.
19. Hastings R., Trautman J., Enna C., Jacobson R. Thalidomide in the treatment of erythema nodosum leprosum. With a note on selected laboratory abnormalities in erythema nodosum leprosum. Clin. Pharmacol. Ther. 4:1970;481-487.
20. Sheskin J., Convit J. Results of a double blind study of the influence of thalidomide on the lepra reaction. Int. J. Lepr. Other Mycobact. 37:1969;135-146.
21. Iyer C., Languillon J., Ramanujam K., Tarabini-Castellani G., De las Aguas J., Bechelli L., Uemura K., Martinez Dominguez V., Sundaresan T. WHO coordinated short-term double blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull. World Health Organ. 45:1971;719-732.
22. Pearson J., Vedagiri M. Treatment of moderately severe erythema nodosum leprosum with thalidomide - a double blind controlled trial. Lepr. Rev. 40:1969;111-116.
23. Waters M. An internally-controlled double-blind trial of thalidomide in severe erythema nodosum leprosum. Lepr. Rev. 42:1971;26-42.
24. Longitudinal study of thalidomide in ENL, United States Public Health Service (Ongoing). Investigational New Drug. 11:(359):date.
25. Arunthathi S., Ebenezer G., Sugumaran S. Nocardia farcinica pleuritis in a lepromatous patient with severe necrotizing reaction: an unusual presentation. Int. J. Lepr. 69:2001;104-107.
26. Nishimura K., Hashimoto Y., Iwasaki S. Enhancement of phorbol ester induced production of tumor necrosis factor alpha by thalidomide. Biochem. Biophys. Res. Comm. 199:1994;455-460.
27. Shannon E., Sandoval F. Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-α by mononuclear cells. Immunopharm. Immunotox. 18:1996;59-72.
28. Sarno E., Grau G., Vieira L., Nery A. Serum levels of TNF-α and IL-1β during leprosy reactional states. Clin. Exp. Immunol. 84:1991;103-108.
29. Shannon E., Ejigu M., Haile-Mariam H., Berhan T., Tasesse G. Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in peripheral blood. Lepr. Rev. 63:1992;5-11.
30. Bhattacharya S., Chattapadhaya D., Saha K. Tumor necrosis factor: status in reactions in leprosy before and after treatment. Int. J. Dermatol. 32:1993;436-439.
31. Handley J., Shields M., Dodge J., Walsh M., Bingham A. Chronic bullous disease of childhood and ulcerative colitis. Pediatr. Dermatol. 10:1993;256-258.
32. Moreira A., Sampaio E., Zmuidzinas A., Frindt P., Smith K., Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J. Exp. M. 177:1993;1675-1680.
33. Moreira A., Kaplan G. Comparison of pentoxifylline, thalidomide and prednisone in the treatment of ENL. Int. J. Lepr. 62:1998;61-65.
34. Khanolkar-Young S., Rayment N., Brickell P., Katz D., Vinayakumar S., Colston M., Lockwood D. Tumor necrosis factor-alpha (TNF-alpha) synthesis is associated with the skin and peripheral nerve pathology of leprosy reversal reactions. Clin. Exp. Immunol. 99:1995;196-202.
35. Wolfenstein P., Latarjet J., Roujeau J., Duguet C., Boudeau S., Vaillant L., Maignan M., Schumacher M., Milpied B., Pilorget A., Bocquet H., Brun-Buisson C., Revuz J. Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet. 352:1998;1586-1589.
36. Corral L., Kaplan G. Immunomodulation by thalidomide and thalidomide analogues. Ann. Rheum. Dis. 58:1999;I107-I113.
37. Frederickson R., Slater I., Dusenberry W., Hewes C., Jones G., Moore R. A comparison of thalidomide and pentobarbital-new methods for identifying novel hypnotic drugs. J. Pharm. Exp. Ther. 202:1977;240-251.
38. Somers G.F. Pharmacological properties of thalidomide (α-phthalimido glutarimide), a new sedative hypnotic drug. Brit. J. Pharmacol. 15:1960;111-116.